Assembly Biosciences Inc Total Assets
Assembly Biosciences Inc total assets. Based on the latest financial reports, Assembly Biosciences Inc (ASMB) holds total assets worth $330.83 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Assembly Biosciences Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Assembly Biosciences Inc (2008–2025)
Total assets of Assembly Biosciences Inc from 2008 to 2025. This chart illustrates how Assembly Biosciences Inc's total assets have evolved over time, based on quarterly financial data. See ASMB stock price for real-time trading data and today's change.
Assembly Biosciences Inc - Asset Composition Analysis
Assembly Biosciences Inc Total Assets Breakdown (December 2025)
Assembly Biosciences Inc total assets breakdown as of December 2025. Assembly Biosciences Inc's total assets of $330.83 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $974.00K | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Assembly Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ASMB working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Assembly Biosciences Inc's current assets represent 98.8% of total assets in 2025, an increase from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 1.8% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 0.4% of total assets.
Assembly Biosciences Inc Competitors by Total Assets
Key competitors of Assembly Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Assembly Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.99 | 1.64 | 12.61 |
| Quick Ratio | 13.99 | 1.64 | 12.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $304.53 Million | $30.18 Million | $173.29 Million |
Assembly Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between Assembly Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.70 |
| Latest Market Cap to Assets Ratio | 1.57 |
| Asset Growth Rate (YoY) | 116.2% |
| Total Assets | $257.59 Million |
| Market Capitalization | $404.57 Million USD |
Valuation Analysis
Above Book Valuation: The market values Assembly Biosciences Inc's assets above their book value (1.57x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Assembly Biosciences Inc's assets grew by 116.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Assembly Biosciences Inc (2008–2025)
The table below shows the annual total assets of Assembly Biosciences Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $257.59 Million | +116.16% |
| 2024-12-31 | $119.17 Million | -12.90% |
| 2023-12-31 | $136.82 Million | +34.41% |
| 2022-12-31 | $101.79 Million | -46.72% |
| 2021-12-31 | $191.06 Million | -32.55% |
| 2020-12-31 | $283.25 Million | -18.58% |
| 2019-12-31 | $347.89 Million | +29.79% |
| 2018-12-31 | $268.05 Million | +58.32% |
| 2017-12-31 | $169.30 Million | +72.55% |
| 2016-12-31 | $98.12 Million | -26.64% |
| 2015-12-31 | $133.74 Million | +87.78% |
| 2014-12-31 | $71.23 Million | +162.51% |
| 2013-12-31 | $27.13 Million | +31.99% |
| 2012-12-31 | $20.56 Million | -44.51% |
| 2011-12-31 | $37.05 Million | +153.45% |
| 2010-12-31 | $14.62 Million | +8691.73% |
| 2009-12-31 | $166.25K | -80.90% |
| 2008-12-31 | $870.39K | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase … Read more